2022 - Research.com Best Scientist Award
2020 - Fellow, National Academy of Inventors
2017 - Warren Alpert Foundation Prize For their collective contributions to the pre-clinical foundation and development of immune checkpoint blockade, a novel form of cancer therapy that has transformed the landscape of cancer treatment.
His main research concerns Immunology, T cell, Cytotoxic T cell, Cell biology and CD28. As part of the same scientific family, Gordon J. Freeman usually focuses on Immunology, concentrating on Blockade and intersecting with Immunotherapy. His T cell study typically links adjacent topics like Molecular biology.
Gordon J. Freeman focuses mostly in the field of Cytotoxic T cell, narrowing it down to matters related to Cancer research and, in some cases, Immune checkpoint, Stem cell and PD-L1. His Cell biology study incorporates themes from Inducible T-Cell Co-Stimulator Protein, Interleukin 2, Receptor, Cytokine and Programmed Cell Death 1 Ligand 2 Protein. His CD28 study combines topics in areas such as Jurkat cells, Naive B cell, Cellular differentiation and Cell–cell interaction.
Immunology, T cell, Immune system, Cell biology and Cancer research are his primary areas of study. His work carried out in the field of Immunology brings together such families of science as Blockade and Virology. The study incorporates disciplines such as Cytotoxic T cell, Nucleic acid and Molecular biology in addition to T cell.
The various areas that Gordon J. Freeman examines in his Immune system study include Cell and Antibody. He has researched Cell biology in several fields, including Receptor, Ligand, Programmed Cell Death 1 Ligand 2 Protein and Cytokine. His Cancer research research focuses on Immunotherapy and how it connects with Oncology.
Gordon J. Freeman spends much of his time researching Cancer research, Immunotherapy, Immune system, Blockade and Immune checkpoint. His Cancer research research incorporates themes from Cancer, Antibody, CD8 and T cell. Gordon J. Freeman applies his multidisciplinary studies on T cell and Dimer in his research.
Gordon J. Freeman has included themes like Cell, Lung cancer, Leukemia and Lymphoma in his Immune system study. The concepts of his Blockade study are interwoven with issues in Phenotype, Ovalbumin, Immunology, Chronic infection and Cytotoxic T cell. Gordon J. Freeman has included themes like CD28, Inhibitory postsynaptic potential and Cell biology in his Receptor study.
Gordon J. Freeman mainly investigates Cancer research, Immunotherapy, Immune system, CD8 and Immune checkpoint. Gordon J. Freeman has researched Immunotherapy in several fields, including Tumor microenvironment, Antibody and Oncology. His Immune system study is mostly concerned with T cell and PD-L1.
His work carried out in the field of T cell brings together such families of science as Cyclin-dependent kinase, Biophysics and Cancer immunotherapy. His CD8 study combines topics in areas such as Cytotoxic T cell, Carcinoma and Clear cell renal cell carcinoma. His work is dedicated to discovering how Immune checkpoint, Cell biology are connected with Viral disease, Vesicle and Flow cytometry and other disciplines.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
Gordon J. Freeman;Andrew J. Long;Yoshiko Iwai;Karen Bourque.
Journal of Experimental Medicine (2000)
PD-1 and its ligands in tolerance and immunity.
Mary E. Keir;Manish J. Butte;Gordon J. Freeman;Arlene H. Sharpe.
Annual Review of Immunology (2008)
Restoring function in exhausted CD8 T cells during chronic viral infection
Daniel L. Barber;E. John Wherry;David Masopust;Baogong Zhu.
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell;Alexander M. Lesokhin;Alexander M. Lesokhin;Ivan Borrello;Ahmad Halwani.
The New England Journal of Medicine (2015)
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Yvette Latchman;Clive R. Wood;Tatyana Chernova;Divya Chaudhary.
Nature Immunology (2001)
THE B7 FAMILY REVISITED
Rebecca J. Greenwald;Gordon J. Freeman;Arlene H. Sharpe.
Annual Review of Immunology (2005)
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Cheryl L Day;Daniel E Kaufmann;Photini Kiepiela;Julia A Brown.
CD4+CD25high Regulatory Cells in Human Peripheral Blood
Clare Baecher-Allan;Julia A. Brown;Gordon J. Freeman;David A. Hafler.
Journal of Immunology (2001)
CTLA-4 can function as a negative regulator of T cell activation
Theresa L. Walunas;Deborah J. Lenschow;Christina Y. Bakker;Peter S. Linsley.
The B7–CD28 superfamily
Arlene H Sharpe;Gordon J Freeman.
Nature Reviews Immunology (2002)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: